Robert Coury - 2010 CEO Pay

Robert Coury - Mylan

Mylan CEO Robert Coury

Total Compensation: $22.9 million

Details: CEOs of generics companies also can see huge rewards. Mylan's Robert Coury saw his compensation increase again last year. In 2009, Coury took in just under $16.5 million, compared with about $13.2 million in 2008. Last year, his base salary increased to $1.7 million--that's up from about $1.57 million the previous year. And his stock options doubled--going from $3 million in 2009 to just over $6 million last year.

Coury is granted use company aircraft for vacations and other personal purposes "in light of heightened security concerns," according to the company's proxy statement. BNET's Jim Edwards points out Coury's jet use stands out among pharma CEOs. In fact, the CEO made use of his company's aircraft more than five times more often than J&J CEO William Weldon and ex-Pfizer CEO Jeff Kindler.

Last year, Mylan had net earnings of $223.6 million, or 68 cents per share, up from $93.5 million, or 30 cents per share, in 2009. It also reported total revenue of $5.4 billion for 2010, up from $5.1 billion for 2009, as the Pittsburgh Business Times reports.

Mylan News:
Mylan - Top 10 Generic Drug Companies 2010
Robert Coury - 2009 CEO Pay

Robert Coury - 2010 CEO Pay

Suggested Articles

Celltrion Chairman Seo Jung-jin says the South Korean company will spend about $33 billion over a decade on its biologics and pharma businesses.

Purdue took a big hit when it settled with Oklahoma over claims it misleadingly advertised its powerful opioid, OxyContin. Now more states want in.

The new endorsement of Celgene's Revlimid from England's cost watchdog NICE may not help calm fears about BMS' $74 billion buyout.